Rosuvastatin Counteracts Vessel Arterialisation and Sinusoid Capillarisation, Reduces Tumour Growth, and Prolongs Survival in Murine Hepatocellular Carcinoma

Figure 1

Rosuvastatin prolongs survival and delays tumour growth in HCC mice. (a) Survival rate of untreated mice (𝑛=6) and rosuvastatin-treated mice (𝑛=6). Data are mean ± SEM, ^∗∗∗𝑃<.001. (b) Liver weight in normal mice (N) and in untreated and rosuvastatin-treated HCC mice (𝑛=4/group) at 16 weeks. Data are mean ± SEM, ^∗∗𝑃<.01, ^∗∗∗𝑃<.001. (c) Representative images of normal livers (N) and untreated and rosuvastatin-treated HCC livers. (𝑛=4/group). Liver and nodule sizes were reduced under rosuvastatin treatment. (d) Representative images of haematoxylin-eosin (HE) staining in normal livers (N) and untreated and rosuvastatin-treated HCC livers (𝑛=4/group) at 16 weeks. Asterisks (*) indicate nodules. (e) Quantification of the nodule surface in untreated and rosuvastatin-treated HCC livers (𝑛=4/group) at 16 weeks. Data are expressed as mean ± SEM (^∗∗𝑃<.01).

(a)

(b)

(c)

(d)

(e)